Foreign Industry Unites Against Annual Japan Price Cuts
This article was originally published in PharmAsia News
Major groups representing the foreign innovation-based pharma and medtech industries in Japan have come out in strong united opposition to a proposal to adopt annual, rather than biennial, reimbursement price cuts, warning this could adversely affect investment and the provision of healthcare.
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.
Join us for a brief audio roundup of the major developments in the international biopharma industry over the past week, as covered by Scrip's global team.